One fact has emerged clearly over the past two years: There are too many uncontrollable variables that can compromise clinical trials.
How can life sciences companies prevent delays and disruptions of their clinical trials? By giving serious thought to decentralizing them. GEP’s new bulletin, Decentralized Clinical Trials: How Procurement Can Help Pharma Companies Prevent and Mitigate Disruptions, defines the necessary criteria to evaluate when outsourcing DCTs. Further, it examines the crucial role procurement has to play in identifying and selecting the right partner.